Search Results

Endologix Reports 30-Day Data From the Ovation LUCY Study

May 31, 2017—Endologix, Inc. announced 30-day results from the LUCY study, which is an evaluation of endovascular aneurysm repair (EVAR) using the company's ultra-low-profile (14-F) Ovation abdominal stent graft system in women with abdominal aortic aneurysms (AAAs).

Endologix's Ovation LUCY Study Completes Patient Enrollment

February 14, 2017—Endologix, Inc. announced that it has completed patient enrollment for the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for Abdominal Aortic AneurYsm Repair) study.

Endologix Reports 1-Year Results From the LUCY Study

June 28, 2018—Endologix, Inc. announced that 1-year results from the LUCY registry were reported at the Society for Vascular Surgery's 2018 Vascular Annual Meeting held June 20–23 in Boston, Massachusetts.

Enrollment Begins in TriVascular's LUCY Study

August 24, 2015—TriVascular, Inc. announced that the first patient was enrolled and treated in the LUCY study, which seeks to study endovascular aneurysm repair (EVAR) in women, who are underrepresented candidates for abdominal aortic aneurysm (AAA) repair.  According to TriVascular, the LUCY study is a prospective, consecutively enrolling, nonrandomized multicenter postmarket registry designed to evaluate the company’s ultra-low-profile (14-F) Ovation abdominal stent graft platform when used in the endovascular treatment of AAA in women compared to men.  The primary objective of the LUCY study is to demonstrate the clinical outcomes and benefits associated with using the Ovation abdominal stent graft platform in both women and men, including low rates of access-related vascular complications, low mortality rates, and high eligibility rates, even in patients who tend to have small access vessel diameters and challenging aortic neck anatomy.